STK11 and neoplasm: Metformin interferes with the proliferation of AML cells by inhibiting the activation of mTOR through the liver kinase B1 (LKB1)/5’ adenosine monophosphate-activated protein kinase (AMPK)/tuberous sclerosis protein (TSC) tumor suppressor axis while sparing normal hematopoiesis [58].